日本化学療法学会雑誌第51巻第4号
|
|
|
- こうき じゅふく
- 5 years ago
- Views:
Transcription
1 Methicillin resistant Staphylococcus aureusmrsa.methicillin resistant S. epidermidismrse.0 MRSA MRSE arbekacinabkquinupristindalfopristinqprdpr vancomycin MIC0. ml Streptococcus pneumoniae penicillinpc intermediate S. pneumoniaepisppc resistant S. pneumoniaeprsp.0. PRSP cefpiromecarbapenemscbps teicoplaninteic QPRDPR 0. ml Enterococcus faecalis Enterococcus faecium TEIC linezolid MIC0. ml MRSAMRSE MIC Enterococcus casseriflavus Enterococcus gallinarum TEIC MRSEStaphylococcus haemolyticus CBPs Bacteroides fragilisprevotella spp CBPs Key words: vancomycin 000 MIC I PCs: benzylpenicillinpcg cefpirome cefoselis cefoperazonecpz cefmetazolecmz latamoxeflmoxflomoxef FMOXcefaclor cefdinir cefpodoxime cefteram cefditorenceftibutencetb cefcapenes 00 CBPs: imipenem U.S.Pharmacopeiameropenem panipenem doripenem No.S : faropenem ampicillinamoxicillinampc FRPMAGs: CEPs: cefazolin tobramycintob arbekacinabk cefotiamu. S. Pharmacopeia NQs: ofloxacin ceftriaxone ceftazidimeu. S. Pharmacopeiacefozopran ciprofloxacinu. S. PharmacopeialevofloxacinORTHO McNEIL
2 tosufloxacintflx MLs: erythromycin clarithromycinu. S. PharmacopeiarokitamycinRKM azithromycinu. S. Pharmacopeia GPTs: vancomycin teicoplaninteic : sulbactamsbtu. S. Pharmacopeia minocyclineminolinezolidlzd quinupristindalfopristinqprdpr fosfomycinfom sulfamethoxazol trimethoprimst LZDQPRDPR MANUALOFCLINICAL MICROBIOLOGYSEVENTH EDITION MIC 0 MIC MIC Staphylococcus aureus ATCC Escherichia coli ATCC Enterococcus faecalis ATCC Streptococcus pneumoniae ATCC Bacteroides fragilis ATCC Bacteroides thetaiotaomicron ATCC Mueller Hinton medium MHMDifcoS. pneumoniae MHM yeast extract 0. streptococci MHM MIC Wilkins Chalgren AgarWCADifco MIC II MIC Tables MIC Tables Staphylococcus S. aureus S. aureus MPIPC MIC. mlmethicillin susceptible S. aureus MSSA.MIC. ml methicillin resistant S. aureusmrsa.mssa MRSA Tables MSSA CEPs MIC0. ml MLs MIC0 00 ml MRSA ABKQPRDPR TEIC ST MIC0. ml LZD MIC0 MIC0. ml MIC0 ml S. aureus ABKQPRDPRTEIC ST. ml LZD MIC. ml. S. epidermidis S. epidermidis MPIPC MIC 0.0 ml methicillin susceptible S. epidermidismsse.0mic 0. ml methicillin resistant S. epidermidismr- SE0.0MSSE MRSE 0 Tables lactam MSSE MIC0. ml MRSE MIC0. ml MRSE QPRDPRABK MINO LZD MIC0. ml TEIC MIC. ml. QPRDPRABK LZD. ml QPR DPR 0. ml S. haemolyticus S. haemolyticus Table
3 000 Table Susceptibility distribution of clinical isolates of MSSA SBT MPIPC SBTCPZ 0 CMZ FMOX 0 0 S FRPM TOB ABK TFLX RKM MINO 00 0 TEIC LZD 0 QPRDPR 0 0 ST FOM Methicillin susceptible Staphylococcus aureusmpipc MIC: ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
4 Table Susceptibility distribution of clinical isolates of MRSA SBT MPIPC SBTCPZ CMZ 0 00 FMOX S FRPM TOB ABK TFLX RKM MINO TEIC 0 LZD QPRDPR ST FOM Methicillin resistant Staphylococcus aureusmpipc MIC: ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
5 000 Table Susceptibility distribution of clinical isolates of MSSE SBT MPIPC SBTCPZ CMZ FMOX 0 S FRPM TOB ABK TFLX RKM MINO 00 TEIC 0 LZD QPRDPR 00 0 ST 00 FOM 0 Methicillin susceptible StaphylococcusepidermidisMPIPC MIC: 00 ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
6 Table Susceptibility distribution of 0 clinical isolates of MRSE SBT MPIPC SBTCPZ CMZ 0 00 FMOX S FRPM TOB ABK TFLX RKM MINO 0 TEIC 0 LZD QPRDPR 00 0 ST 00 FOM Methicillin resistant StaphylococcusepidermidisMPIPC MIC: 0 ml MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
7 000 Table Susceptibility distribution of clinical isolates of Staphylococcus haemolyticus SBT MPIPC SBTCPZ CMZ 00 FMOX S FRPM TOB ABK TFLX RKM MINO 0 0 TEIC LZD QPRDPR ST 00 FOM 00 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
8 Table Susceptibility distribution of 0 clinical isolates of Staphylococcus saprophyticus SBT MPIPC SBTCPZ CMZ FMOX S FRPM TOB ABK TFLX RKM MINO 0 0 TEIC LZD 0 QPRDPR ST FOM 0 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
9 000 Table Susceptibility distribution of clinical isolates of Staphylococus lugdunensis MIC ml SBT MPIPC 00 0 SBTCPZ 0 0 CMZ FMOX 0 S FRPM TOB ABK TFLX RKM MINO TEIC LZD 0 QPRDPR ST FOM 0 : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
10 Table Susceptibility distribution of clinical isolates of Staphylococcus warneri MIC ml SBT MPIPC SBTCPZ CMZ FMOX 0 0 S FRPM TOB ABK TFLX RKM MINO TEIC 0 0 LZD QPRDPR 0 0 ST FOM 00 SBT: strains : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
11 000 Table Susceptibility distribution of clinical isolates of Staphylococcus capitis MIC ml SBT MPIPC 0 00 SBTCPZ CMZ 00 FMOX 00 S FRPM TOB ABK TFLX RKM MINO 00 TEIC LZD QPRDPR 0 ST FOM MIC ml : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
12 Table 0 Susceptibility distribution of clinical isolates of miscellaneous coagulase negative staphylococci* MIC ml SBT MPIPC SBTCPZ CMZ 0 FMOX 0 S FRPM TOB ABK TFLX RKM MINO 00 0 TEIC LZD 0 QPRDPR 0 ST FOM 0 00 *S. caprae strains, S. hominis strains, strain each of S. cohnii, S. hyicus, S. schleiferi, and S. simulans : ampicillin, SBT: sulbactamampicillin, MPIPC: oxacillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, TOB: tobramycin, ABK: arbekacin, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim, FOM: fosfomycin
13 000 Table Susceptibility distribution of 0 clinical isolates of Streptococcus pyogenes AMPC SBT CPZ CMZ FMOX 00 0 S FRPM TFLX MINO 00 TEIC LZD QPRDPR 0 0 ST : ampicillin, AMPC: amoxicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim QPRDPR ABKLZD MIC0. ml. ml TEIC MIC0 ml MIC ml. S. saprophyticus S. saprophyticus 0 Table lactam MIC0. ml lactam RKM MLs MIC. ml
14 Table Susceptibility distribution of clinical isolates of Streptococcus agalactiae AMPC SBT CPZ CMZ FMOX 0 S FRPM TFLX MINO 0 00 TEIC LZD QPRDPR 0 ST : ampicillin, AMPC: amoxicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim S. lugdunensis S. lugdunensis Table lactam MIC0. ml lactam MLsTOB MIC. ml S. warneri S. warneri Table MLs FOM TOB MIC0. ml MIC
15 000 ml TEIC MIC ml S. capitis S. capitis Table MIC0. ml ABKQPRDPR MINOTEIC LZD. mlst. ml. ml MIC0 Other coagulase negative Staphylococci S. caprae S. hominis S. cohnii S. hyicus S. schleiferi S. simulans Table 0 MINOABKQPRDPR TEIC MIC0. ml lactam MLs FOM S. caprae S. simulans CBPsNQs RKM MLs MIC. ml Streptococcus S. pyogenes S. pyogenes 0 Table CBPs MIC ml AMPC S 00 MIC0 0.0 ml MLsMIC: 0. ml.0minomic:. ml. S. agalactiae S. agalactiae Table MINO MIC0. ml NQsMIC:. ml.mino. S. pneumoniae S. pneumoniae PCG MIC 0.0 ml penicillinpc susceptible S. pneumoniaepssp.mic 0.0 ml 0. ml PC intermediate S. pneumoniaepisp.mic. ml PC resistant S. pneumoniaeprsp 0.PSSPPISP PRSP 0 Tables PSSP lactam MIC0 0. ml CBPs MIC0 0.0 ml CBPs MIC0 PISP mlprsp ml lactam MIC0 PSSP PISP PRSP TEICQPRDPR LZD PSSPPISP PRSP MIC0 NQs PSSP PRSP PRSP ml MIC MLs PSSP PSSP PRSP PSSP PISP PRSP MIC0 MIC0 S. mitis groups. sanguis group S. mitis groups. sanguis group Table S. mitis CBPs lactam MLsMINO ST TEICTFLXQPRDPR MIC0 0. ml S. anginosus group S. anginosus group Table lactam 0. ml MIC0 CBPs 0.0 ml MLs Enterococcus E. faecalis E. faecalis Table TEICLZD MIC ml MIC0. ml NQs MLs ml MIC 0.. TEIC. ml E. faecium E. faecium Table
16 Table Susceptibility distribution of clinical isolates of penicillin susceptible Streptococcus pneumoniaepssp PCG SBT AMPC CPZ CMZ 0 FMOX S FRPM TFLX RKM MINO TEIC LZD QPRDPR 0 ST PCG MIC: 00 ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim
17 000 Table Susceptibility distribution of clinical isolates of penicillin intermediate Streptococcus pneumoniaepisp PCG SBT AMPC CPZ CMZ FMOX 0 0 S FRPM TFLX RKM MINO TEIC LZD QPRDPR 0 0 ST 0 PCG MIC: 0 ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim
18 Table Susceptibility distribution of clinical isolates of penicillin resistant Streptococcus pneumoniaeprsp PCG SBT AMPC 0 0 CPZ CMZ FMOX S FRPM TFLX RKM MINO TEIC LZD QPRDPR 0 ST PCG MIC: ml PCG: benzylpenicillin, : ampicillin, SBT: sulbactamampicillin, AMPC: amoxicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, RKM: rokitamycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim
19 000 Table Susceptibility distribution of clinical isolates of the Streptococcus mitis groupstreptococcus sanguis group SBT CPZ CMZ 00 FMOX 0 S FRPM TFLX MINO 00 TEIC LZD QPRDPR 0 ST strains S. mitis strains, S. oralis strains, strain each of S. sanguis, S. parasanguis, and S. gordonii : ampicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim TEICLZDQPRDPR MIC ml TEIC LZD QPRDPR. ml E. avium E. avium 0 Table 0 ST TEICTFLX MIC0. ml ST TFLX ml
20 Table Susceptibility distribution of clinical isolates of the Streptococcus anginosus group SBT CPZ CMZ FMOX 0 S FRPM TFLX MINO 00 TEIC LZD QPRDPR 0 0 ST 00 0 S. anginosus strains, S. constellatus strains, S. intermedius strains : ampicillin, SBT: sulbactamampicillin, : cefazolin, : cefotiam, : ceftriaxone, : ceftazidime, CPZ: cefoperazone, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefteram, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, MINO: minocycline, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim MIC TEIC. ml E. raffinosus E. raffinosus Table ST TEIC. ml E. casseriflavus E. gallinarum E. casseriflavus E. gallinarum
21 000 Table Susceptibility distribution of clinical isolates of Enterococcus faecalis FRPM 0 0 TFLX TEIC 0 LZD QPRDPR ST MIC ml : ampicillin, : cefozopran, : cefpirome, : cefoselis, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : erythromycin, : clarithromycin, : azithromycin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristin dalfopristin, ST: sulfamethoxazole trimethoprim Table Susceptibility distribution of clinical isolates of Enterococcus faecium TFLX TEIC LZD QPRDPR 0 0 ST 0 00 MIC ml : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim
22 Table 0Susceptibility distribution of 0 clinical isolates of Enterococcus avium TFLX 0 TEIC LZD 0 QPRDPR 0 0 ST 0 : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Table Susceptibility distribution of clinical isolates of Enterococcus raffinosus TFLX TEIC LZD QPRDPR ST 00 0 MIC ml : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Table E. casseriflavus NQs ST E. gallinarum lactamsnqsst vanc.. ml MIC Peptostreptococcus spp. P. anaerobius 0 P. micros P. magnus P. asaccharolyticus P. hydrogenalis P. vaginalis P. bamesae P. ivorii 0 Table
23 000 Table Susceptibility distribution of chinical isolates of Enterococcus casseliflavus and Enterococcus gallinarum E. casseliflavus strains TFLX 0 TEIC LZD QPRDPR ST 0 E. gallinarum strains TFLX 0 TEIC LZD QPRDPR ST 0 00 : ampicillin, : imipenem, : meropenem, : panipenem, : doripenem, : ofloxacin, : ciprofloxacin, : levofloxacin, TFLX: tosufloxacin, : vancomycin, TEIC: teicoplanin, LZD: linezolid, QPRDPR: quinupristindalfopristin, ST: sulfamethoxazole trimethoprim Peptostreptococcus spp MIC0 0. ml. ml MIC0 CETB CEPs ml MIC CBPs. ml MIC P. anaerobius P. bamesae. ml P. bamesae C. difficile C. difficile Table C. difficile MIC0:. ml PCGMIC0:. ml P. acnes P. acnes Table S 00 MIC0
24 Table Susceptibility distribution of clinical isolates of Peptostreptococcus spp CMZ 00 LMOX FMOX CETB S FRPM *P. anaerobius, 0strains, P. micros strains, strains each of P. magnus, and P. asaccharolyticus, P. hydrogenalis strains, strain each of P. vaginalis, P. bamesae, and P. ivorii : ceftazidime, : cefozopran, : cefpirome, : cefoselis, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefaclor, : cefdinir, : cefpodoxime, : cefditoren, CETB: ceftibuten, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem, : vancomycin Table Susceptibility distribution of clinical isolates of Clostridium difficile PCG FMOX PCG: benzylpenicillin, FMOX: flomoxef, : imipenem, : meropenem, : panipenem, : doripenem, : vancomycin 0.0 ml. ml B. fragilis B. fragilis Table FRPM MIC0 0. ml CBPs. ml. ml MIC0 CEPs LMOXFMOX. ml MIC0 Other B. fragilis group B. thetaiotaomicron B. distasonis B. uniformis B. vulgatus Other B. fragilis group Table B. fragilis FRPM MIC0... ml Prevotella spp.
25 000 Table Susceptibility distribution of clinical isolates of Propionibacterium acnes FMOX CETB S :cefotiam, FMOX:flomoxef, :cefaclor, :cefdinir, :cefpodoxime, : cefteram, :cefditoren, CETB:ceftibuten, : cefcapene, :vancomycin Table Susceptibility distribution of clinical isolates of Bacteroides fragilis SBTCPZ CMZ LMOX FMOX S FRPM 00 0 : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefdinir, : cefpodoxime, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem P. bivia P. melaninogenica P. intermedia P. oralis P. loesheii P. buccae P. corporis P. oris Table CBPs MIC0 0. ml FMOX MIC0. ml CEPs MIC0 00 ml FMOX 00 ml MIC P. bivia III 000 LZD QPRDPR resistant
26 Table Susceptibility distribution of clinical isolates of miscellaneous members of the Bacteroides fragilis group* SBTCPZ CMZ 0 0 LMOX FMOX 00 0 S FRPM 0 *B. thetaiotaomicron strains, B. distasonis strains, B. uniformis strains, B. vulgatus strains : ceftazidime, : cefozopran, : cefpirome, : cefoselis, SBTCPZ: sulbactamcefoperazone, CMZ: cefmetazole, LMOX: latamoxef, FMOX: flomoxef, : cefdinir, : cefpodoxime, : cefditoren, : cefcapene, FRPM: faropenem, : imipenem, : meropenem, : panipenem, : doripenem Table Susceptibility distribution of clinical isolates of Prevotella spp FMOX *P. bivia strains, P. melaninogenica strains, P. intermedia strains, strains each of P. oralis, and P. loescheii, straineach of P. buccae, P. corporis, and P. oris : ceftazidime, : cefozopran, : cefpirome, : cefoselis, FMOX: flomoxef, : imipenem, : meropenem, : panipenem, : doripenem EnterococciVRE LZD National Committee for Clinical Laboratory StandardsNC- CLS MIC ml S. aureusmsse E. faecalis E. casseriflavus MIC. ml LZD MRSA Tsiodras VRE Gonzales E. faecalis E. faecium Johnson QPRDPR NS MIC ml E. faecalis E. raffinosus. ml MIC Enterococcus MIC. ml Fluit MRSA MIC ml
27 000 Sanches MRSA MRSEmethicillin resistant S. haemolyticusmrsh other methicillin resistant coagulase negative StaphylococciMRCNS MRSA TEIC NS TEIC ml ml TEIC. ml MIC MRSE 0 S. haemolyticus S. warneri. ml MIC vanc E. casseriflavus E. gallinarum Sanches Staphylococcus TEIC MRSE.MRSH., Staphylococcus TEIC 00 vana MRSA Morbidity and Mortality Weekly ReportMMWR: 00 MMWR 0: 000 Centers for Disease Control and PreventionCDC S. aureus MRSA MRSA MRSA MRSA ABKQPRDPR ST. ml ABK MIC ml QPRDPR Diekema S. epidermidis MRSE MRSE S. epidermidis Coagulase negative staphylococcicns ABKLZDQPRDPR TEIC MRSE S. haemolyticus TEIC S. aureus S. pyogenes lactam S. pyogenes MLs Farrell 0 MLs.. S. pneumoniae PISP PRSPPISPPCG MIC ml PRSPPCG MIC. ml PISPPRSP PISPPRSP 000 PISPPRSP PRSP Felmingham Adam Doern Low Perez Trallero PSSPPISPPRSP Ubukata NS PCG MIC PCG MIC PSSP
28 PRSP PBP S. pneumoniae PISP+PRSP : 00 :. 0 : 0. :. :. :. :. PSSP 0 0 PRSP CBPsTFLX TEIC 0. ml MIC0 NQs ml MIC Yokota. VRE Karlowsky 0 E. faecalis E. faecium. VRE E. faecalis, E. faecium, E. avium, E. raffinosus, E. casseriflavus, E. gallinarum E. casseriflavus, E. gallinarum E. casseriflavus, E. gallinarum TEICLZD. ml E. faecalis MIC. ml MIC ml NQs MIC: ml Enterococcus NQs Peptostreptococcus spp MIC0 0. ml MIC0. ml MIC. ml P. bamesae C. difficile MIC0. ml Pelaez. B. fragilis MIC0 0.0 ml. ml MIC0. ml. ml B. fragilis CBPs Wexler MIC0 0 Prevotella spp CBPs MIC0 MIC0 B. fragilis MRSA CNS vana VRSA VISA VRE PRSP LZD QPRDPR
29 000 : Chemotherapy : : Chemotherapy : 0 : Chemotherapy : 0 : Chemotherapy : : Chemotherapy : : : 0000 : : Manual of Clinical Microbiology Seventh Edition: American Society for MicrobiologyWashingtonD. C., MIC : MICChemotherapy : 0 MIC : MICChemotherapy : 0 National Committee for Clinical Laboratory StandardsNS: TwelfthInformational Supplement M00 SPerformance Standards for Antimicrobial Susceptibility Testing. WaynePA: NS00 Tsiodras SGold H SSakoulasG et al.: Linezolid resistance in a clinical isolate of Staphylococcus aureus. LANCET : 0000 Gonzales RSchreckenberger P CGraham M Bet al.: Infections due to vancomycin resistant Enterococcus faecium resistant to linezolid. LANCET : 00 Johnson A PTysall LStockdale M Wet al.: Emerging Linezolid Resistant Enterococcus faecalis and Enterococcus faecium Isolated from Two Austrian Patients in the Same Intensive Care Unit. Eur. J. Clin. Microbiol. Infect. Dis. : 00 Fluit A CWielders C L CVerhoef Jet al.: Epidemiology and Susceptibility of 0 Staphylococcus aureus Isolates from University Hospitals Participating in the European SENTRY Study. J. Clin. Micribiol. : 00 Sanches I SMato RLancastre H Det al.: Patterns of Multidrug Resistance among Methicillin Resistant Hospital Isolates of Coagulase Positive and Coagulase Negative Staphylococci Collected in the International Multicenter Study RESIST in and. Microb. Drug Resist. : 000 : 000 Jpn. J. Antibiotics : 00 Diekema D JPfaller M AJones R Net al.: Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the USACanada and Latin America. Int. J. Antimicrob. Agents. : 000 : 000 Jpn. J. Antibiotics : Farrell D JMorrissey IBakker Set al.: Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 000 study. J. Antimicrob. Chemother. 0S : 00 : 000 Jpn. J. Antibiotics : 00 : cefpodoxime Jpn. J. Antibiotics : 00 Felmingham DReinert R RHirakata Y., et al.: Increasing prevalence of antimicrobial resistance amaong isolates of Streptococcus pneumoniae from the PROTECT surveillance studyand comparative in vitro activity of the ketolidetelithromycin. J. Antimicrob. Chemother. 0S : 00 Adam D: Grobal antibiotic resistance in Streptococcus pneumoniaej. Antimicrob. Chemother. 0:T : 00 Doern G VHeilmann K PHuynh H Ket al.: Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in the United States during 000Including a Comparison of Resistance Rate since. Antimicrob. Agents Chemother. : 00 LowDEAzovedo J DWeiss Ket al.: Antimicrobial Resistance among Clinical Isolates of Streptococcus pneumoniae in Canada during 000. Antimicrob. Agents Chemother. : 000 Perez Trallero EFernandez Mazarrasa CGarcia Rey Cet al.: Antimicrobial Susceptibilities of
30 Streptococcus pneumoniae and 0 Streptococcus pyogenes Isolates and Their Ecological Relationships: Results of a Year Multicenter Surveillance Study in Spain. Antimicrob. Agents Chemother. : 000 Ubukata KMuraki TIgarashi Aet al.: Identification of Penicillin and other Beta Lactam Resistance in Streptococcus pneumoniae by Polymerase Chain Reaction. J. Infect. Chemother. : 0 Yokota SSato KKuwahara Oet al.: Fluoroquinolone Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. : 00 0 Karlowsky J AKelly L JCritchley I Aet al.: Determining Linezolid s Baseline In Vitro Activity in Canada Using Gram Positive Clinical Isolates Collected prior to Its National Rerease. Antimicrob. Agents Chemother. : 00 : VanAE. faecalis : : VRE linezolid 0: 000 : VRE : 000 Pelaez TAlcala LAlonso Ret al.: Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin. Antimicrob. Agents Chemother. : 000 Wexler H MMolitoris DSt. John Set al.: InVitro Activities of Faropenem against Strains of Anaerobic Bacteria. Antimicrob. Agents Chemother. : 00 Surveillance of susceptibility of clinical isolates of various bacterial species to antibacterial s Antimicrobial activity against gram positive cocci and anaerobic bacteria isolated in 000 Isamu YoshidaYoshiji KimuraIsao Higashiyama Giichi Sugimori and Yoshinori Yamano Discovery Research LaboratoriesShionogi & Co., Ltd., Futaba cho ToyonakaOsaka 0Japan The activity of various antibacterial s against clinical isolates of strains of gram positive cocci0 speciesand strains of anaerobic bacteria specieswas assessed by determining their agar dilution MICs. The strains testedwere clinical isolates obtained in 000 at facilities in Japan. Methicillin resistant strains accounted for. of the Staphylococcus aureus and for.0 of the Staphylococcus epidermidisarbekacinabkquinupristindalfopristinqprdprand vancomycin had high antibacterial activity against methicillin resistant S. aureusmrsaand methicillin resistant S. epidermidismrsewith MIC0 values. ml. PenicillinPC intermediate strains and PC resistant strains accounted for. and 0.respectivelyof the Streptococcus pneumoniae CefpiromecarbapenemsCBPsteicoplaninTEICand QPRDPR displayed high antibacterial activity against PRSPinhibiting the growth of all strains at 0. ml. TEICand linezolid were effective against Enterococcus faecalis and Enterococcus faecium with MIC0 values. ml. No resistant strains were found among the gram positive coccus isolates testedincluding MRSA MRSEand Enterococcus speciesexcept Enterococcus casseriflavus and Enterococcus gallinarumhowever TEIC resistant strains were detected in some speciessuch as MRSE and Staphylococcus haemolyticus Among the anaerobescbps displayed potent antibacterial activity against all anaerobic bacteriahowever thedecrease in susceptibility of Bacteroides fragilis and Prevotella spp. to CBPs should be noted.
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
Dec THE JAPANESE JOURNAL OF ANTIBIOTICS ( 45 ) ) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 1
Dec. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 46 431 ( 45 ) 2006 1) 1) 2) 2) 3) 4) 4,5) 6) 6) 7) 8) 8) 9) 10) 11) 11) 12) 13) 13) 14) 14) 15) 15) 16) 16) 17) 17) 1) 1) 1) 2) 3) 4) 5) 6) 7) 8) 9) 10)
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis
Streptococcus pneumoniae,streptococcus pyogenes,streptococcus agalactiae,neisseria gonorrhoeae,h.influenzae,moraxella subgenus Branhamella catarrharis, E.coil,Klebsiella pneumoniae,klebsiella oxytoca,proteus
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
1.Streptococcus pneumoniae, Streptococcus pyogenes JC-1,S.aureus Smith,methicillin (DMPPC)- susceptible S. aureus subsp. aureus (MSSA) TR101, DMPPC-resistant S. aureus subsp. aureus (MRSA) TR102, Staphylococcus
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
03-b-„FŒ{›xŒ¾-4.02
518( 30 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 Dec. 25 2003 1. * * Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 6 519( 31 ) 9 5 2003 8 2004 7 14 565 701 258 (36.8%) 443 (63.2%) Staphylococcus aureus
02-(a)-Łi’ì™·Łv-4.11
THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 105( 13 ) 2001 1) 2) 3) JA 2 7 1) 2) 3) 106( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 56 2 Apr. 1982 7 2001 (2001.4 2002.3) 1 221 175 (79.2%) 420 186 234 Staphylococcus
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
70( 70 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. Meropenem 2002 * * * * * * * * * * * * * * * * * * * * * * NTT Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 71( 71 ) * * * * 2003 12 22 Meropenem
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 Feb Neisseria gonorrhoeae ceftriaxone CTRX % 2010 CTRX 20 FQ staphylococci, E. faecium, N.
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 1 1 2013 69 11,762 2015 11 16 1994 2013 69 19 11,762 FQ 33 Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae
Aug THE JAPANESE JOURNAL OF ANTIBIOTICS (9) 2007 NTT JA
Aug. 2009 THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 277 (9) 2007 NTT JA 278 (10) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 Aug. 2009 2009 4 10 1982 7 2007 2007 4 2008 3 1 229 181 (79.0%) 683 24 395 288
Apr THE JAPANESE JOURNAL OF ANTIBIOTICS ( 13 ) 2008 NTT
Apr. 2010 THE JAPANESE JOURNAL OF ANTIBIOTICS 63 12 105 ( 13 ) 2008 NTT 106 ( 14 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 2 Apr. 2010 JA 2010 1 27 1982 7 2008 2008 4 2009 3 1 215 173 (80.5%) 694 18 357
DIC vegetation 1 nonbacterial thrombogenic e
2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 33( 33 ) 2002 JA * 1 * 2 2003 12 15 * 1) * 2) 34( 34 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 1982 7 2002 (2002.4 2003.3) 1 174 131 (75.3%) 334 171 163 Staphylococcus
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk
VOL. 30 S-3 CHEMOTHERAPY imeumoniae, Serratia marcescens, Proteus sp, CHEMOTHERAPY DEC. 1982 Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus,
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
CHEMOTHERAPY Methicillin-resistant S.aureus(MRSA) coccus epidermidis 105 Streptococcus pyogenes E.faecali senterococcus avium Enterococcus faecium Str
cefaclor(ccl),cefuroxime(cxm),cefixime (CFIX),cefteram(CFTM),cefdinir(CFDN) pneumoniae,streptococcus pyogenes Moraxella catarrhalis,haemophilus influenzae,escherichia coli, Klebsiella pneumoniae,proteus
THE JAPANESE JOURNAL OF ANTIBIOTICS 63 13 243 ( 37 ) 2007 12 2008 5 19 863 methicillin-susceptible Staphylococcus aureus (MSSA) Escherichia coli levof
242 ( 36 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 prulifloxacin * ** ** CMC * ** 2010 2 22 Prulifloxacin ulifloxacin (UFX) 3 1 2003 12 2004 5 19 534 2 2005 12 2006 5 19 805 3 THE JAPANESE JOURNAL OF
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon
Feb. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 1 1 2008 2009 2011 10 25 2008 6 2009 4 Streptococcus pneumoniae 377 penicillin-binding protein: PBP 2004 S. pneumoniae 160 2 2 THE JAPANESE JOURNAL OF
PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC= Piperacillin
Key words : Clinical isolates, Antibacterial susceptibility, Scale of hospital PCG = Benzylpenicillin ABPC= Ampicillin AMPC= Amoxicillin MPIPC = Oxacillin MCIPC = Cloxacillin SBPC= Sulbenicillin PIPC=
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
CHEMOTHERAPY OCT. 1994 Tazobactam Piperacillin Fig. I. Chemical structures of tazobactam and piperacillin. Table 1. Media used for preculture and MIC determination BHIB: Brain heart infusion broth (Difco),
Table 1. Antibacterial activity of cefdinir, cefixime, cefteram, cefuroxime, cefaclor and amoxicillin against standard strains Inoculum size: 108 cells/ml CFDN: cefdinir, CFIX: cefixime, CFTM: cefteram,
600mg 600mg CTD 2 2.5 2.5 Page 3 2.5...7 2.5.1...7 2.5.2...27 2.5.3...28 2.5.4...42 2.5.5...55 2.5.6...79 2.5.7...97 2.5 Page 5 73 67 31 48 48A 102 104 105 106 ALP ALT(GPT) AST(GOT) AUC AUEC BID BUN
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 11( 11 ) 2003 12 17 (MRSA) penicillin-resistant Streptococcus pneumoniae (PRSP) 3 I. 12( 12 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 1 Feb. 3 1997 1) (1985)
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
Table 1. Antibacterial activity of azithromycin and other agents against gram-positive anaerobic bacteria and facultative anaerobic bacteria a Facultative anaerobic bacteria. Table 2. Antibacterial activity
Helicobacter pylori Helicobacter pylori Helkobacter pylori erythromycin (EM) Mueller Hinton broth (Difco) H. pylori Staphylococcus aureus ATCC 29213 Escherichia coli ATCC25922 amoxicillin (AMPC), clarithromycin
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
CHEMO THE RAPY OCT. 1994
bilis (0.78), Proteus vulgaris (1.56), Enterococcus faecalis (3.13), Staphylococcus epidermidis (6.25), Klebsiella pneumoniae (6.25), Morganella morganii (6.25), Escherichia coli (12.5), Providencia rettgeri
R06_01
Staphylococcus aureus (MSSA) PCG (N=118,334) 57,369 (48.5%) 判定不能 :3 (0.0%) 60,962 (51.5%) CEZ (N=143,723) I:42 (0.0%) 143,635 (99.9%) R:46 (0.0%) CVA/AMPC (N=19,281) R:14 (0.1%) 19,265 (99.9%) 判定不能 :2
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab
June 2011 THE JAPANESE JOURNAL OF ANTIBIOTICS 64 23 179 ( 63 ) A b cefditoren pivoxil 5 amoxicillin 10 1,2) 1,3) 1) 1) 1) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 2011 4 8 2007 5 2009 4 A b GAS cefditoren pivoxil
49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e
Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC
2.7 臨床概要
2.7 臨床概要 A/G Al-P ALT AST AT- AUC AZM BIPM BP BUN CEZ CFPN-PI CFU CLcr Cmax CNS COPD CPFX CRP CS CYP CVA DBT DHP-I DIC DRPM DRPM-DC FAS γ-gtp GCP GNB GNF-GNR GPB HAM - Staphylococcus C P450 -I Full Analysis
VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
日本化学療法学会雑誌第53巻第S-1号
Doripenem in vitro Doripenem in vitro 7 7 3 DRPM in vitro DRPM 00 DRPM Staphylococcus Streptococcus µ gml MIC90 Moraxella catarrhalishaemophilus influenzae µ gml MIC90 imipenem IPM panipenem meropenemmepm
1BD BBLCRYSTAL RGP Aerococcus viridans Arcanobacterium pyogenes Bacillus cereus Bacillus licheniformis Bacillus megaterium Bacillus pumilus Bacillus s
111-245150-N-03 21400AMY00151000 20099 1 BD BBLCRYSTAL RGP BD BBLCRYSTAL RGP 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J 1-J -D-
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
N-03.indd
111-24514035-N-03 21300AMY00325000 20099 1 BD BBLCRYSTAL GP BD BBLCRYSTAL GP g/ 4-A 7--4-0.175 2-A -D- 4---D- 1.692 1-A L--7--4-1.7775 4-B L--7--4-2.182 2-B -D- 4---D- 1.6915 1-B L--7--4-1.4315 4-C L--7--4-2.3815
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates
Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates Table 2-1. Summary of patients treated with grepafloxacin for respiratory infection 1) Out: outpatient,
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
日本化学療法学会雑誌第50巻第6号
13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin Table 1 Differentiation of group D streptococcia aderived from R.R.Facklam1,2),K.C.Gross-et al3),and
日本化学療法学会雑誌第58巻第4号
Escherichia coli Enterococcus faecalisstreptococcus agalactiae Klebsiella pneumoniae Staphylococcus epidermidis E. colie. faecalispseudomonas aeruginosa K. pneumoniae S. agalactiae E. coli E. coli μ p
CHEMOTHERAPY DEC phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepac
CHEMOTHERAPY DEC. 1988 phvlococcus aureus Staphylococcus Enterococcus faecalis Escherichia Klebsiella pneumoniae Serratia marcescens Pseudomonas cepacia 1 Bacteroides bivius Propionibacterium granulosum
THE JAPANESE JOURNAL OF ANTIBIOTICS ( 79)
346 ( 78) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 2007 72 12,919 NTT THE JAPANESE JOURNAL OF ANTIBIOTICS 62 44 347 ( 79) 348 ( 80) THE JAPANESE JOURNAL OF ANTIBIOTICS 62 _ 4 THE JAPANESE JOURNAL OF
untitled
111-245010-N-04 21300AMY00327000 20116 2 20099 1 BD BBLCRYSTAL ANR BD BBLCRYSTAL ANR 4-A 2-A 1-A 4-B 2-B 1-B 4-C 2-C 1-C 4-D 2-D 1-D 4-E 2-E 1-E 4-F 2-F 1-F 4-G 2-G 1-G 4-H 2-H 1-H 4-I 2-I 1-I 4-J 2-J
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Assoc
J Infect Chemother (2012) 18:609 620 DOI 10.1007/s10156-012-0434-3 SURVEILLANCE Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of
* Antibiotic resistance: PCG, penicillinase positive; DMPPC, methicillin and other Ĉ-lactams; EM, macrolides and lincomycins; KM, producing a 3'-phosphotransferase; GM, producing a dual enzyme having
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin
Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
43 Acontum apoiense 17 19581147 1988 17 2001 A4 A4 H17. 4.20. 3. 1012 131421 IT 50 10,340 11,521 2 3 8 9 9 10 10 15 19 20 21 21 1617 22 23 1904 1928 1940 Nature MRSA MRCNS VREVRSA PRSP BRNAR MDRP ESBL)MBL
untitled
Seminal paper Anhalt JP Pioneering paper Claydon MA Kishnamurthy T Enterobacter B. cereus Routine identification paper Eigner U Seng P Cherkaoui A Saureus S. Saureus* S. Vagococcus Haemophilus Mycobacterium
概要 (2006 年 1 2 3 月分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動 向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 2005 年 2006 年 10~12
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT
Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 121 23 7 7 IDSA 122 24 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr. 2012 7 2005 3 10 7 2011 6 2 NTT NTT 2011 6 Apr. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
Pseudomonas aeruginosa S-827 Fig. 1. Method of biofilm formation. Table 1. Susceptibilities of antimicrobial agents on agar plate and in broth against Pseudomonas aeruginosa S-827 JULY CHEMOTHERAPY 888
CHEMOTHERAPY 34 T-2588の APR.1986 嫌 気 性 菌 に 対す る抗 菌 作 用 に つ い て 沢 赫 代 神 野 英 毅 青 木 誠 小 林 と よ子 渡 辺 邦 友 上 野 一 恵 岐阜大学医学部附属嫌気性菌実験施設 新 し く 開 発 さ れ た 経 口 用 エ ス テ ル 型 セ フ ェ ム 系 抗 生 剤T-2588の 口 剤 で あ るcephalexin(CEX),cefaclor(CCL)
01-a-‹ä‘㑼‰v-4.03
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 5 425( 1 ) Telithromycin 7 20 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) Telithromycin (TEL) TEL ermb mefa
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT
June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 181 27 201072 12,866 JA 182 28 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 June 2012 NTT June 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 3 183 29 2012 3
概要 (2004 年分 ) 本サーベイランスは 参加医療機関において血液および髄液から分離された各種細菌の検出状況や薬剤感受性パターンの動向を把握するとともに 新たな耐性菌の早期検出等を目的とする これらのデータを経時的に解析し臨床の現場に還元することによって 抗菌薬の安全で有効な使用方法や院内感染制御における具体的かつ確実な情報を提供する 検体 ( ) 内は施設数 2002 年 2003 年 2004
VOL.30 NO.10 CHEMOTHERAPY 1123 Fig,1 Group B case 6 hepatolithiasis,e.k.66 y.0.,f.45kg Postoperative wound infection Fig.2 Group B case 15 gastric cancer,k.k.60 y.o.,m. Postoperative peritonitis Fig.3